California Ends Medicaid Coverage of Weight Loss Drugs Despite TrumpRx Plan
SACRAMENTO, Calif. — Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year. Health officials are recommending diet and exercise as alternatives to heavily advertised weight loss drugs like Wegovy and Zepbound, advice experts say is unrealistic. “Of course he tried eating well […]
JCM, Vol. 15, Pages 541: Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss
JCM, Vol. 15, Pages 541: Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss Journal of Clinical Medicine doi: 10.3390/jcm15020541 Authors: Gunjan Arora Katherine R. Conde Cyrus V. Desouza Introduction: Overweight and obesity are becoming increasingly prevalent. Incretin-based obesity treatments—glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide […]
Bull of the Day: Eli Lilly (LLY)
Eli Lilly Company Overview Zacks Rank #1 (Strong Buy) Eli Lilly and Company (LLY) is one of the world’s largest and most diversified pharmaceutical companies. The Indiana, Indianapolis-based company offers a pharma product category that includez neuroscience (Cymbalta/Emgality), cardiometabolic health (Mounjaro, Zepbound, Trulicity, and others), oncology (Alimta, Cyramza, and Verzenio), immunology (Taltz, Omvoh, and Olumiant), […]
New Report: Aesthetics Market Growth Cools With Maturation As GLP-1 Boom Tempers
The American aesthetics market is entering a more mature phase, marked by slower growth, greater category divergence and a shift toward operational efficiency rather than rapid expansion, according to a new report from med-spa data analytics firm Guidepoint Qsight and healthcare investment bank Skytale. The report, called “Defining … The post New Report: Aesthetics Market […]
Donald Trump says he has never taken the ‘fat drug’ Ozempic, but this White House official has…
President Donald Trump told The New York Times he has not used GLP-1 weight-loss drugs like Ozempic or Wegovy but joked he “probably should.” The disclosure comes as these medications spark debates over healthcare costs and insurance coverage. Trump’s remarks highlight both his personal health and his administration’s policies aimed at lowering drug prices, showing […]
I lost 5st on Mounjaro but brushed off deadly warning signs – my liver was like an alcoholic’s and I lost an organ
WHEN Abbie Taylor began using fat jabs she was transfixed by the results. Like millions on the GLP-1 drugs, the 26-year-old marvelled at her rapid weight loss, shedding a whopping 4.5st in a matter of months. Little did she know, the ‘miracle’ injections were to leave Abbie on the brink of death not once, but…
Weight loss wonder drug GLP-1 could be game-changing in addiction treatment
Early signs show popular weight loss drugs may curb more than just food cravings. GLP-1’s like Ozempic, Mounjaro may also help patients with addiction. — Subscribe to ABC News on YouTube: https://abcnews.visitlink.me/59aJ1G ABC News is your daily source of breaking national and world news, exclusive interviews and 24/7 live streaming coverage. https://abcnews.go.com/ Download the ABC […]
Pills, TikTok and apps: the consumer-driven future of weight loss jabs
Ask executives in the healthcare industry about the future market for weight-loss drugs and the analogies are telling: monthly GLP-1 medicine subscriptions like a streaming video membership; dose decisions managed on a smartphone app; access made as easy as buying a pair of Nikes. This is their vision of the consumerisation of weight-loss as drugmakers Novo Nordisk and Eli […]
Global analysis shows widespread eligibility for GLP-1 weight management drugs
The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers.
[Correspondence] GLP-1 receptor agonists for obesity: eligibility across 99 countries
Obesity is a complex, multifactorial condition defined by excessive adiposity and associated health risks.1 The rising prevalence of obesity contributes to the increasing global burden of obesity-related diseases, such as type 2 diabetes and cardiovascular diseases, placing immense strain on health-care systems and economies worldwide. Behavioural interventions, such as diet and exercise, have long been […]